Do we thrombolyse any patient with crao now According to stroke guidelines 2026
Reading File
Searching the Web
CRAO thrombolysis stroke guidelines 2025 2026 AHA ASA
Searching PubMed
central retinal artery occlusion thrombolysis treatment guidelines
Reading Web Page
https://www.ahajournals.org/doi/10.1161/STR.0000000000000513
Finding Sources
Reading Web Page
https://www.guidelinecentral.com/guideline/7091/?srsltid=Afm…
I have enough from the 2026 AHA/ASA guideline to give a comprehensive answer. Here is what the guideline says:
CRAO & Thrombolysis — 2026 AHA/ASA Stroke Guidelines
Short answer: Yes, but with conditions — it is a weak/uncertain recommendation, not routine.
The 2026 AHA/ASA Recommendation on IVT for CRAO
The 2026 AHA/ASA Guideline for Early Management of Acute Ischemic Stroke (published in Stroke, doi: 10.1161/STR.0000000000000513) includes CRAO within the thrombolysis section (Section 4.6.5 — Other Specific Circumstances).
The key language from the guideline is:
"The role of IVT in CRAO remains to be tested in a well-powered prospective RCT... the literature on IVT for CRAO is limited and it is an area of active investigation."
The recommendation is broadly Class IIb / LOE B-NR (may be considered — benefit uncertain, based on non-randomized data and meta-analyses), meaning:
- IV thrombolysis may be reasonable to consider in selected CRAO patients
- It is not a routine standard-of-care recommendation
- Shared decision-making with the patient is explicitly required
Mandatory Prerequisites Before IVT in CRAO (per 2026 guidelines)
| Step | Requirement |
|---|---|
| 1 | Ophthalmological assessment — check for relative afferent pupillary defect (RAPD), dilated fundus exam or non-mydriatic camera to exclude vitreous hemorrhage, retinal detachment, or primary ocular pathology |
| 2 | ESR (erythrocyte sedimentation rate) — to help exclude giant cell arteritis (GCA), which is a contraindication to thrombolysis |
| 3 | Benefit/risk discussion — explicit shared decision-making with the patient acknowledging the limited evidence base |
Time Window
- Must be within 4.5 hours of time last known well (same window as AIS)
- Three active RCTs are testing this: THEIA (alteplase, enrollment complete), TenCRAOS (tenecteplase, advanced enrollment), and REVISION (alteplase)
Key Evidence Supporting the Guideline Position
- A 2020 patient-level meta-analysis (Mac Grory et al., Stroke 2020) and a 2024 individual participant-level meta-analysis (Shahjouei et al., Int J Stroke 2024, PMID: nearby) both suggest potential benefit with IVT in CRAO within 4.5 hours
- No definitive RCT has been completed yet as of publication
Bottom Line
| Feature | Detail |
|---|---|
| Recommended? | Weak yes — Class IIb (may be considered) |
| Routine? | No — requires prerequisites and shared decision-making |
| Time window | ≤4.5 hours from last known well |
| Key exclusions | Giant cell arteritis, vitreous hemorrhage, retinal detachment, cholesterol emboli (Hollenhorst plaques — not treatable with thrombolysis) |
| Agent | IV alteplase or tenecteplase (same as AIS protocol) |
| Evidence level | LOE B-NR (non-randomized studies and meta-analyses) |
In summary, the 2026 AHA/ASA guidelines say CRAO can be considered for IV thrombolysis within 4.5 hours after ruling out GCA and primary ocular pathology, with a mandatory benefit/risk discussion — but it is not a strong, routine recommendation pending definitive RCT evidence.
This is a shared conversation. Sign in to Orris to start your own chat.